Skip to main content

Advertisement

SpringerLink
Log in

Treatment of obesity-associated overactive bladder by the phosphodiesterase type-4 inhibitor roflumilast

  • Urology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Purpose

To prove that phosphodiesterase type-4 inhibitors could potentially treat obesity-associated overactive bladder through modulation of the systemic inflammatory response.

Methods

In this 12-week study, 90 female Sprague–Dawley rats were divided into three groups: (1) vehicle-treated normal diet (ND)-fed rats; (2) vehicle-treated high-fat diet (HFD)-fed rats; and (3) roflumilast-treated HFD-fed rats. Oral roflumilast (5 mg/kg/day) was administered during the last 4 weeks of HFD feeding in the test group. At 12 weeks, a urodynamic study was performed in ten rats of each group. Bladder tissue was extracted, the bladder mucosa was separated under microscopy, and bladder detrusor smooth muscle (DSM) expression of TNF-α, interleukin (IL)-6, IL-1β, and nuclear factor kappa B (NF-κB) were analyzed using Western blotting and quantitative reverse transcription-polymerase chain reaction (qRT-PCR).

Results

Bodyweights of the HFD-fed rats significantly increased and were not ameliorated by roflumilast treatment. Cystometry evidenced augmented frequency and non-void contractions in obese rats that were also prevented by roflumilast. These alterations were accompanied by a markedly increased expression of TNF-α, IL-6, IL-1β, and NF-κB in DSM of obese rats. Furthermore, roflumilast decreased expression of inflammatory factors in DSM.

Conclusions

Oral treatment with roflumilast in rats fed an HFD restores normal bladder function and downregulates expression of inflammatory factors in the bladder.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Drake MJ (2014) Do we need a new definition of the overactive bladder syndrome? ICI-RS 2013. Neurourol Urodyn 33(5):622–624

    Article  PubMed  Google Scholar 

  2. Gulur DM, Drake MJ (2004) Management of overactive bladder. Dis Manage Health Outcomes 350(2):786–799

    Google Scholar 

  3. Wen JG, Li JS, Wang ZM, Huang CX, Shang XP, Su ZQ, Lu YT, Suo ZH, Wang Y, Qin GJ (2014) The prevalence and risk factors of OAB in middle-aged and old people in China. Neurourol Urodyn 33(4):387–391

    Article  PubMed  Google Scholar 

  4. Laven BA, Orsini N, Andersson SO, Johansson JE, Gerber GS, Wolk A (2008) Birth weight, abdominal obesity and the risk of lower urinary tract symptoms in a population based study of Swedish men. J Urol 179(5):1895–1896

    Article  Google Scholar 

  5. Wellen KE, Gs H (2003) Obesity-induced inflammatory changes in adipose tissue. J Clin Investig 112(12):1785–1788

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Haldar S, Dru C, Choudhury D, Mishra R, Fernandez A, Biondi S, Liu Z, Shimada K, Arditi M, Bhowmick NA (2015) Inflammation and pyroptosis mediate muscle expansion in an interleukin-1beta (IL-1beta)-dependent manner. J Biol Chem 290(10):6574–6583. doi:10.1074/jbc.M114.617886

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Bouchelouche K, Alvarez S, Horn T, Nordling J, Bouchelouche P (2006) Human detrusor smooth muscle cells release interleukin-6, interleukin-8, and RANTES in response to proinflammatory cytokines interleukin-1β and tumor necrosis factor-α. Urology 67(1):214–219

    Article  PubMed  Google Scholar 

  8. Rohrmann S, Smit E, Giovannucci E, Platz EA (2005) Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). Prostate 67(15):1693–1698

    Article  Google Scholar 

  9. Rahman NU, Phonsombat S, Bochinski D, Carrion RE, Nunes L, Lue TF (2007) An animal model to study lower urinary tract symptoms and erectile dysfunction: the hyperlipidaemic rat. BJU Int 100(3):658–663

    Article  PubMed  Google Scholar 

  10. Leiria LO, Sollon C, Calixto MC, Lintomen L, Mónica FZ, Anhê GF, De NG, Zanesco A, Grant AD, Antunes E (2012) Role of PKC and CaV1.2 in detrusor overactivity in a model of obesity associated with insulin resistance in mice. PLoS ONE 7(11):e48507–e48507

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Staskin DR, Robinson D (2009) Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder. Expert Opin Pharmacother 10(18):3103–3111

    Article  CAS  PubMed  Google Scholar 

  12. Schafer PH, Truzzi F, Parton A, Wu L, Kosek J, Zhang LH, Horan G, Saltari A, Quadri M, Lotti R, Marconi A, Pincelli C (2016) Phosphodiesterase 4 in inflammatory diseases: effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4/CD271 complex. Cell Signal 28(7):753–763. doi:10.1016/j.cellsig.2016.01.007

    Article  CAS  PubMed  Google Scholar 

  13. Sturton G, Fitzgerald M (2002) Phosphodiesterase 4 inhibitors for the treatment of COPD. Chest 121(5 Suppl):192S–196S

    Article  CAS  PubMed  Google Scholar 

  14. Oger S, Behr-Roussel D, Gorny D, Denys P, Lebret T, Alexandre L, Giuliano F (2007) Relaxation of phasic contractile activity of human detrusor strips by cyclic nucleotide phosphodiesterase type 4 inhibition. Eur Urol 51(3):772–780; discussion 780–781

    Article  CAS  PubMed  Google Scholar 

  15. Longhurst PA, Briscoe JA, Rosenberg DJ, Leggett RE (1997) The role of cyclic nucleotides in guinea-pig bladder contractility. Br J Pharmacol 121(8):1665–1672

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Xin W, Li N, Cheng Q, Petkov GV (2014) BK channel-mediated relaxation of urinary bladder smooth muscle: a novel paradigm for phosphodiesterase type 4 regulation of bladder function. J Pharmacol Exp Ther 349(1):56

    Article  PubMed  PubMed Central  Google Scholar 

  17. Hansen MJ, Jovanovska V, Morris MJ (2004) Adaptive responses in hypothalamic neuropeptide Y in the face of prolonged high-fat feeding in the rat. J Neurochem 88(4):909–916

    Article  CAS  PubMed  Google Scholar 

  18. Fan EW, Chen LJ, Cheng JT, Tong YC (2014) Changes of urinary bladder contractility in high-fat diet-fed mice: the role of tumor necrosis factor-alpha. Int J Urol 21(8):831–835. doi:10.1111/iju.12428

    Article  CAS  PubMed  Google Scholar 

  19. Li N, He X, Li Z, Liu Y, Wang P (2016) Partial bladder outlet obstruction is associated with decreased expression and function of the small-conductance Ca2+-activated K+ channel in guinea pig detrusor smooth muscle. Int Urol Nephrol 49(1):17–26. doi:10.1007/s11255-016-1455-0

    Article  PubMed  Google Scholar 

  20. Li N, Ding H, He X, Li Z, Liu Y (2017) Expression and function of the small-conductance Ca2+-activated K+ channel is decreased in urinary bladder smooth muscle cells from female guinea pig with partial bladder outlet obstruction. Int Urol Nephrol. doi:10.1007/s11255-017-1592-0

    Google Scholar 

  21. Bulló M, García-Lorda P, Megias I, Ph.D. JS-SMD (2003) Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression. Obes Res 11(4):525–531

    Article  PubMed  Google Scholar 

  22. Conti M, Richter W, Mehats C, Livera G, Park JY, Jin C (2003) Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J Biol Chem 278(8):5493–5496. doi:10.1074/jbc.R200029200

    Article  CAS  PubMed  Google Scholar 

  23. Essayan DM (1999) Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation. Biochem Pharmacol 57(9):965–973

    Article  CAS  PubMed  Google Scholar 

  24. de Heredia FP, Gómezmartínez S, Marcos A (2012) Obesity, inflammation and the immune system. Proc Nutr Soc 71(71):332–338

    Article  PubMed  Google Scholar 

  25. Lee MK, Yvan-Charvet L, Masters SL, Murphy AJ (2016) The modern interleukin-1 superfamily: divergent roles in obesity. Semin Immunol. doi:10.1016/j.smim.2016.10.001

    PubMed Central  Google Scholar 

  26. Fry CH, Sahai A, Vahabi B, Kanai AJ, Birder LA (2014) What is the role for biomarkers for lower urinary tract disorders? ICI-RS 2013. Neurourol Urodyn 33(5):602–605. doi:10.1002/nau.22558

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Schäfer W, Abrams P, Liao L, Mattiasson A, Pesce F, Spangberg A, Sterling AM, Zinner NR, Kerrebroeck PV (2002) Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies. Neurourol Urodyn 21(3):261–274

    Article  PubMed  Google Scholar 

  28. Seki S, Sasaki K, Fraser MO, Igawa Y, Nishizawa O, Chancellor MB, de Groat WC, Yoshimura N (2002) Immunoneutralization of nerve growth factor in lumbosacral spinal cord reduces bladder hyperreflexia in spinal cord injured rats. J Urol 168(168):2269–2274

    Article  CAS  PubMed  Google Scholar 

  29. Yoon J, Ryoo S (2013) Arginase inhibition reduces interleukin-1beta-stimulated vascular smooth muscle cell proliferation by increasing nitric oxide synthase-dependent nitric oxide production. Biochem Biophys Res Commun 435(3):428–433. doi:10.1016/j.bbrc.2013.05.002

    Article  CAS  PubMed  Google Scholar 

  30. Abrams P, Andersson KE (2007) Muscarinic receptor antagonists for overactive bladder. BJU Int 100(5):987–1006. doi:10.1111/j.1464-410X.2007.07205.x

    Article  CAS  PubMed  Google Scholar 

  31. Andersson KE (2016) Potential future pharmacological treatment of bladder dysfunction. Basic Clin Pharmacol Toxicol 119(3 Suppl):75–85

    Article  CAS  PubMed  Google Scholar 

  32. Truss MC, Uckert S, Stief CG, Forssmann WG, Jonas U (1996) Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle. I. Effect of various PDE inhibitors on smooth muscle tone and cyclic nucleotide levels in vitro. Urolithiasis 24(3):123–128

    CAS  Google Scholar 

  33. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ (2009) Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 374(9691):685–694

    Article  CAS  PubMed  Google Scholar 

  34. Houslay MD, Schafer P, Zhang KY (2005) Phosphodiesterase-4 as a therapeutic target. Drug Discov Today 10(22):1503–1519

    Article  CAS  PubMed  Google Scholar 

  35. Oba Y, Lone NA (2012) Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Ther Adv Respir Dis 7(1):13–24

    Article  PubMed  Google Scholar 

Download references

Funding

This study was funded by a grant from LNCCC of LNCCC-D16-2015 to Ning Li.

Author information

Authors and Affiliations

  1. Department of Urology, Fourth Affiliated Hospital, China Medical University, 4 Chongshan East Road, Shenyang, Liaoning, China

    Honglin Ding, Ning Li, Bing Liu, Liming Dong & Yili Liu

  2. Department of Stomatology, Fourth Affiliated Hospital, China Medical University, 4 Chongshan East Road, Shenyang, Liaoning, China

    Xiaoning He

Authors
  1. Honglin Ding
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ning Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiaoning He
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bing Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Liming Dong
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yili Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ning Li.

Ethics declarations

Conflict of interest

All authors declare that they have no conflict of interests with regard to the work reported in this manuscript.

Ethical approval

All applicable international, national, and institutional guidelines for the care and use of animals were followed.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ding, H., Li, N., He, X. et al. Treatment of obesity-associated overactive bladder by the phosphodiesterase type-4 inhibitor roflumilast. Int Urol Nephrol 49, 1723–1730 (2017). https://doi.org/10.1007/s11255-017-1671-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-017-1671-2

Keywords

Search

Navigation